

Quarterly Activities Report and Appendix 4C


HIGHLIGHTS

- During Q2 FY26, sales of \$3.3 million reflected a seasonal reduction in respiratory testing rates in Australia;
- Revenue contribution originated from all three regions, Australia, EMEA and the US; with international markets contributing a growing share of group revenue;
- Initial U.S. sites are now serving as reference sites to demonstrate the clinical value of our diagnostic solution, to support the acquisition of additional customers;
- UK revenue was underpinned by improving gastroenteric sales performance, reflecting growing momentum with National Health Service (NHS) clientele;
- Continued progress on the development of an automated, high-throughput solution; *and*;
- Strong balance sheet with a \$29.7 million cash and term deposit balance on 31 December 2025, supported by the receipt of \$4.4 million from the Australian Research & Development Tax Incentive.

Operational Update

The Company recorded sales of \$3.3 million (unaudited) for Q2 FY26. Revenue for the quarter reflected a seasonal reduction in respiratory testing rates in Australia.

Figure 1: GSS Quarterly revenue (A\$m)



Receipts from customers for the quarter were \$4.6 million. Net operating cash inflow was \$1.8 million, including \$4.4 million received under the Australian Research and Development Tax Incentive. Net investing cash outflows of \$0.2 million for the quarter included investments in equipment for placement at customer sites and within the Company's R&D laboratories. Payments of fees to Directors, including the CEO, were \$0.3 million for the quarter and are included in 1.2(e) – staff costs of the Appendix 4C.

As of 31 December 2025, Genetic Signatures held a total cash balance of \$29.7 million, comprising \$17.2 million in cash at bank and \$12.5 million in term deposits. While term deposits are classified as 'other financial assets' in the Annual Report, in accordance with accounting standards, they have been included in 'Cash and cash equivalents' in the Appendix 4C, to reflect funds available to the Company for funding future operating activities.

Supporting initial US customer sites to increase throughput

The Company continues to work closely with its three contracted customers to successfully implement the *EasyScreen*™ Gastrointestinal Parasite Detection Kit, providing hands-on commercial and technical support to ensure a smooth onboarding and integration into routine testing workflows.

During Q2 FY26, a second contracted customer went live, with products delivered to site for go-live. The third customer has progressed through implementation activities and operational readiness, with testing expected to commence during the current quarter.

The sales team remains engaged with all contracted customers to support increased testing volumes, focusing on optimising workflows, expanding use cases, and embedding *EasyScreen*™ into standard diagnostic protocols. These initial deployments are now functioning as reference sites, demonstrating clinical and operational value and supporting further customer engagement and conversion across the pipeline.

Team engaged in EMEA to support evaluations of GI portfolio

The team continues to work with multiple NHS trusts in the UK, where Genetic Signatures' GI viral, bacterial, and parasite test kits are being used in hospital settings to support infection control and outbreak prevention. To date, these engagements have generated supportive clinical data, reinforcing the value of our proposition to a growing number of potential clients.

The team continue to pursue further evaluations to facilitate future growth in this region.

Genetic Signatures continues to work with external distribution partners across the EMEA region.

Progress on new instruments and software and R&D

During the quarter, further effort was undertaken to finalise the detailed scope of work which will form the second phase of the development program, focusing on the integrated customisation of both hardware and software components.

A non-customised instrument has been procured by the R&D team to support development activities aimed at enhancing the Company's **3base**® infectious disease syndromic testing menu which will be launched alongside the new integrated platform.

The R&D team continues to optimise workflows across on-market products, with a strong emphasis on increasing automation and improving the usability of existing instrumentation.

Additional investments in research, development and procurement were also made to reduce development risk and strengthen the supply of critical manufacturing components.

Leadership change at Genetic Signatures

During the quarter, the Company advised that Allison Rossiter informed the Board that she will be leaving Genetic Signatures in late February 2026 to take on a role with a global pharmaceutical company. The Board has initiated a search for a CEO to replace Ms Rossiter and will be implementing interim arrangements to maintain continuity of leadership and operations.

In parallel with the search for a CEO, the recruitment process for the CFO role is also progressing.

Outlook

Looking ahead, the Company remains focused on strengthening its presence in Australia while accelerating global expansion. With the initiatives and team we have in place, we remain confident in our ability to continue diversifying revenue by growing international markets beyond our current primarily domestic business. The Company's solid cash position enables continued, targeted investment in commercial initiatives, while also supporting innovation across assay development, workflow optimisation, instrumentation, and software enhancements.

– END –

Announcement authorised by Genetic Signatures' Board of Directors

For further information, see our website (www.geneticsignatures.com) or contact us:

Allison Rossiter
Chief Executive Officer

allison.rossiter@geneticsignatures.com

T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial Officer

karl.pechmann@geneticsignatures.com

Daniel Ireland
Investor Relations

daniel.ireland@datair.com.au

0428 607 884

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics company, specialising in detecting infectious diseases, using patented **3base®** technology to simplify the genetic complexity of pathogen identification. Automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms, in a single test. Genetic Signatures' unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance, improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

GENETIC SIGNATURES LIMITED

ABN

30 095 913 205

Quarter ended ("current quarter")

31 December 2025

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	4,573	10,170
1.2 Payments for		
(a) research and development	(987)	(1,345)
(b) product manufacturing and operating costs	(1,411)	(3,707)
(c) advertising and marketing	(109)	(644)
(d) leased assets	(89)	(194)
(e) staff costs	(3,931)	(7,694)
(f) administration, corporate and other costs	(954)	(2,003)
1.3 Dividends received (see note 3)		
1.4 Interest received	320	714
1.5 Interest and other costs of finance paid	(13)	(28)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	4,382	4,382
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	1,781	(349)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(207)	(599)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(207)	(599)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Principal element of lease payments	(121)	(233)
3.10	Net cash from / (used in) financing activities	(121)	(233)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	28,230	30,873
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,781	(349)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(207)	(599)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(121)	(233)
4.5	Effect of movement in exchange rates on cash held	7	(2)
4.6	Cash and cash equivalents at end of period	29,690	29,690

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	17,190	10,730
5.2	Call deposits	12,500	17,500
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	29,690	28,230

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter
\$A'000**

277

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7. Financing facilities

Note: the term "facility" includes all forms of financing arrangements available to the entity.

Add notes as necessary for an understanding of the sources of finance available to the entity.

7.1 Loan facilities

7.2 Credit standby arrangements

7.3 Other (please specify)

7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000

7.5 **Unused financing facilities available at quarter end**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities**\$A'000**

8.1 Net cash from / (used in) operating activities (Item 1.9)

1,781

8.2 Cash and cash equivalents at quarter end (Item 4.6)

29,690

8.3 Unused finance facilities available at quarter end (Item 7.5)

-

8.4 Total available funding (Item 8.2 + Item 8.3)

29,690

8.5 **Estimated quarters of funding available (Item 8.4 divided by Item 8.1)**

N/A

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 20 January 2026

Authorised by: Board of Directors

(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.